GLENMARK PHARMA Announces Quarterly Results (1QFY20); Net Profit Down 53.1%

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

GLENMARK PHARMA Announces Quarterly Results (1QFY20); Net Profit Down 53.1%
Wed, 28 Aug

GLENMARK PHARMA has announced its results for the quarter ended June 2019. Here is a detailed performance review of the same:

GLENMARK PHARMA Quarterly Financials

No. of Mths
Qtr. Ending
3
Jun-18*
3
Mar-19*
3
Jun-19*
QoQ ChangeYoY Change
Net SalesRs m21,65625,63523,229-9.4%7.3%
Other incomeRs m1,38239117-95.7%-98.8%
TurnoverRs m23,03826,02523,245-10.7%0.9%
ExpensesRs m18,18721,99319,810-9.9%8.9%
Gross profitRs m3,4693,6413,419-6.1%-1.4%
DepreciationRs m79481090712.1%14.3%
InterestRs m79081993013.6%17.7%
Profit before taxRs m3,2672,4031,598-33.5%-51.1%
TaxRs m937786506-35.7%-46.1%
Profit after taxRs m2,3301,6171,093-32.4%-53.1%
Gross profit margin%16.014.214.7
Effective tax rate%28.732.731.6
Net profit margin%10.16.24.7
* Results Consolidated
Interim results exclude extraordinary / exceptional items
Source: Company Reports, Regulatory Filings, Equitymaster


Year-on-Year Performance:
  • The company's operating income during the quarter grew 7.3% on a year-on-year (YoY) basis. The expenses were up by 8.9% YoY during the same period.
  • The company's operating profit declined by 1.4% YoY during the quarter. Consequently, operating profit margins witnessed a decline and stood at 14.7% in 1QFY20 as against 16.0% in 1QFY19.
  • Depreciation charges increased by 14.3% and finance costs increased by 17.7% YoY, respectively.
  • Other income declined by 98.8% YoY during the quarter.
  • Net profit for the quarter declined by 53.1% YoY. Net profit margins during the quarter declined from 10.1% in 1QFY19 to 4.7% in 1QFY20.
Quarter-on-Quarter Performance:
  • The company's operating income during the quarter fell 9.4% on a quarter-on-quarter (QoQ) basis. The expenses were down by 9.9% QoQ during the same period.
  • The company's operating profit declined by 6.1% QoQ during the quarter. Consequently, operating profit margins witnessed a growth and stood at 14.7% in 1QFY20 as against 14.2% in 4QFY19.
  • Net profit for the quarter declined by 32.4% QoQ, while net profit margins declined from 6.2% in 4QFY19 to 4.7% in 1QFY20.

To see how GLENMARK PHARMA has performed over the last eight quarters,please visit here.

GLENMARK PHARMA Share Price Performance

Over the last one year,GLENMARK PHARMA share price has moved down from Rs 643.4 to Rs 377.3, registering a Loss of Rs 266.2 or around 41.4%.

Meanwhile, the S&P BSE HEALTHCARE Index is trading at Rs 12,548.7 (down 0.1%). Over the last one year it has moved down from 15,533.1 to 12,548.7, a gain of 2,984 points (down 19.2%).

Overall, the S&P BSE SENSEX is down 3.2% over the year.

Current Valuations

At the current price of Rs 377.3, the price to earnings (P/E) ratio of GLENMARK PHARMA stands at 12.8 times its trailing twelve months earnings, while its price to book value (P/BV) ratio stands at 2.0 times.

Equitymaster requests your view! Post a comment on "GLENMARK PHARMA Announces Quarterly Results (1QFY20); Net Profit Down 53.1%". Click here!

  

Related Views on News

GLENMARK PHARMA Announces Quarterly Results (1QFY21); Net Profit Up 132.5% (Quarterly Result Update)

Sep 1, 2020 | Updated on Sep 1, 2020

For the quarter ended June 2020, GLENMARK PHARMA has posted a net profit of Rs 3 bn (up 132.5% YoY). Sales on the other hand came in at Rs 23 bn (up 0.9% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

GLENMARK PHARMA Announces Quarterly Results (3QFY20); Net Profit Up 64.0% (Quarterly Result Update)

Feb 19, 2020 | Updated on Feb 19, 2020

For the quarter ended December 2019, GLENMARK PHARMA has posted a net profit of Rs 2 bn (up 64.0% YoY). Sales on the other hand came in at Rs 27 bn (up 7.1% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

GLENMARK PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Sep 5, 2019 | Updated on Sep 5, 2019

Here's an analysis of the annual report of GLENMARK PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of GLENMARK PHARMA. Also includes updates on the valuation of GLENMARK PHARMA.

More Views on News

Most Popular

Hotel Stocks Will Reward Investors(Fast Profits Daily)

Jun 8, 2021

This is why I'm bullish on the hotel and hospitality sector.

Don't Break These 5 Intraday Trading Rules(Fast Profits Daily)

Jun 1, 2021

To become a better intraday trader, follow these rules religiously.

The Most Visible Sign of India's Revival is on Two Wheels(Profit Hunter)

Jun 9, 2021

Investing in the best stocks could result in wealth compounding on a massive scale.

Rs 2 Trillion Stimulus Coming to a Stock Market Near You(Profit Hunter)

Jun 2, 2021

Get ready to profit from a massive stimulus that you've never seen before.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

GLENMARK PHARMA SHARE PRICE


Jun 14, 2021 10:12 AM

TRACK GLENMARK PHARMA

  • Track your investment in GLENMARK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON GLENMARK PHARMA

GLENMARK PHARMA 5-YR ANALYSIS

COMPARE GLENMARK PHARMA WITH

MARKET STATS